Epilepsy - Global Clinical Trial Landscape (2024)

Explore the forefront of epilepsy research with Novotech CRO's comprehensive analysis, unveiling innovative therapies, clinical trials, and future trends shaping epilepsy care.

Epilepsy, characterized by recurrent seizures, presents diverse causes including genetic factors, infections, and metabolic disorders, with idiopathic generalized epilepsy being predominant. Antiepileptic drugs effectively control seizures in up to 70% of cases.

Globally, epilepsy affects 46 million individuals, with the highest prevalence in the Asia-Pacific region. Treatment primarily involves antiepileptic drugs, with emerging options targeting specific subtypes through precision medicine and genetic therapies.

Since 2019, over 4,000 epilepsy trials have been initiated worldwide, with Asia-Pacific leading in trials conducted. Marketed drugs like Likozam and Fycompa, alongside Phase III candidates such as Ztalmy and Ganaxolone, promise advancements in treatment.

Despite global health challenges, ongoing research offers optimism for enhanced management through innovative therapies. Partner with Novotech, a leading CRO with extensive clinical project experience, for comprehensive support in therapeutic development. Access our detailed disease report to delve deeper into epilepsy research.